1998
Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study
Yoshida D, Piepmeier J, Bergenheim T, Henriksson R, Teramoto A. Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study. British Journal Of Cancer 1998, 77: 21-25. PMID: 9459141, PMCID: PMC2151249, DOI: 10.1038/bjc.1998.4.Peer-Reviewed Original ResearchConceptsMatrix metalloproteinase-2Dose-dependent mannerEstramustine groupMetalloproteinase-2Glioma cellsCell invasionMalignant glioma cellsHuman glioma cellsAnti-microtubule agentsControl groupEstramustineMatrix metalloproteinasesInfiltrative capacityCell invasivenessAntimicrotubule agentsCell proliferationSignificant suppressionDisassembly of microtubulesSignificant differencesU87MG cellsLower ratesInvasionHaptoinvasionCellsGroup
1996
Targeting microtubule-associated proteins in glioblastoma: A new strategy for selective therapy
Piepmeier J, Pedersen P, Yoshida D, Greer C. Targeting microtubule-associated proteins in glioblastoma: A new strategy for selective therapy. Annals Of Surgical Oncology 1996, 3: 543-549. PMID: 8915486, DOI: 10.1007/bf02306087.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, AlkylatingBrain NeoplasmsCarrier ProteinsCell LineColony-Forming Units AssayEstramustineFlow CytometryGlioblastomaHumansImmunohistochemistryMiceMice, NudeMicrotubule-Associated ProteinsNeoplasm TransplantationRadiation-Sensitizing AgentsThymidineTransplantation, HeterologousTumor Cells, CulturedConceptsSubcutaneous xenograftsGlioblastoma cellsHuman glioblastoma cellsMicrotubule-associated proteinsHuman glioblastomaPotent antimitotic effectsUse of estramustineAntimicrotubule agentsEstramustine-binding proteinPreclinical dataEstramustineNeoplastic cellsAntiproliferative effectsSelective therapyGlioma cellsAntimitotic effectCytotoxic effectsGlioblastomaUseful targetTherapyXenograftsLaboratory investigationsSelective effectAntimitotic activityCellsEstramustine in malignant glioma
Bergenheim A, Henriksson R, Piepmeier J, Yoshida D. Estramustine in malignant glioma. Journal Of Neuro-Oncology 1996, 30: 81-89. PMID: 8865006, DOI: 10.1007/bf00177446.Peer-Reviewed Original Research
1994
Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes.
Yoshida D, Cornell-Bell A, Piepmeier J. Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes. Neurosurgery 1994, 34: 863-7; discussion 867-8. PMID: 8052384, DOI: 10.1227/00006123-199405000-00012.Peer-Reviewed Original ResearchConceptsAntimitotic effectHuman glioblastoma cellsGlioma cellsGlioblastoma cellsEstramustine binding proteinModest antiproliferative effectsConcentration-dependent cytotoxic effectConcentration-dependent inhibitionEstramustine treatmentImmunohistochemical analysisAstrocyte viabilityEstramustineAstrocyte culturesAntiproliferative effectsMonoclonal antibodiesAstrocytesHuman glioblastomaTumor culturesCytotoxic effectsDimethylthiazol-2Diphenyltetrazolium bromideAntimicrotubule activityDeoxyribonucleic acid synthesisEstramustine sensitizes human glioblastoma cells to irradiation.
Yoshida D, Piepmeier J, Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Research 1994, 54: 1415-7. PMID: 8137240.Peer-Reviewed Original ResearchConceptsMicroM estramustineRadiation enhancerGlioma cellsEffect of estramustineGlioblastoma cellsG2M cellsConcentration-dependent inhibitionMalignant glioma cellsHuman glioma cellsMinimal systemic toxicityEstramustineHuman glioblastoma cellsPotentiation factorSystemic toxicityG2M fractionFlow cytometryClonogenic survivalAntimicrotubule agentsCytotoxic effectsControl cellsH treatmentDaily scheduleCellsCell cycleRadiation sensitivity